GlassScriptPhysician profile
Junie Tilus
NPI 1275032377
$4,707.43
in general payments reported to CMS, 2019-2025
27 companies · $1,851 in 2025
The $1,851 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.28 · 2022: $290 · 2023: $656 · 2024: $1,894 · 2025: $1,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,073 · Education: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,073.38 |
| Education | $327.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.00 | 2022-2025 | |
| Genzyme Corporation | $705.50 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $455.26 | 2022-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $406.50 | 2021-2025 | Tremfya |
| Ucb, INC. | $312.68 | 2024-2025 | Bimzelx |
| Leo Pharma INC. | $238.59 | 2023-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $204.54 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $197.96 | 2022-2025 | Nemluvio, Aklief |
| Strata Skin Sciences, INC. | $181.26 | 2024-2025 | Xtrac |
| Novartis Pharmaceuticals Corporation | $175.17 | 2023-2025 | |
| Lilly USA, LLC | $160.59 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $132.09 | 2024-2025 | |
| Pfizer INC. | $125.95 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Amgen INC. | $59.50 | 2022-2024 | Otezla |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $55.32 | 2022-2024 | Opzelura |
| Revance Therapeutics, INC. | $52.77 | 2025 | Daxxify |
| Hill Dermaceuticals, INC. | $50.85 | 2024 | Tolak |
| Biofrontera INC. | $43.64 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $27.36 | 2024 | Vtama |
| Lnhc, INC | $23.93 | 2025 | Zelsuvmi |
| Fidia Pharma USA INC. | $20.87 | 2025 | |
| Krystal Biotech INC | $19.42 | 2024 | Vyjuvek |
| Paratek Pharmaceuticals, INC. | $18.65 | 2025 | Nuzyra |
| Convatec INC. | $18.47 | 2023 | |
| Botanix Sb INC | $18.39 | 2025 | Sofdra |
| Cipher Pharmaceuticals US LLC | $15.18 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junie Tilus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.